

Resource Summary Report

Generated by [nidm-terms](#) on Aug 16, 2026

Alexa Fluor(R) 647 anti-human CD8

RRID:AB_2563451

Type: Antibody

Proper Citation

BioLegend Cat# 344725, RRID:AB_2563451

Antibody Information

URL: http://antibodyregistry.org/AB_2563451

Proper Citation: BioLegend Cat# 344725, RRID:AB_2563451

Target Antigen: CD8

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: Alexa Fluor(R) 647 anti-human CD8

Description: This monoclonal targets CD8

Target Organism: cynomolgus, rhesus, human

Clone ID: Clone SK1

Antibody ID: AB_2563451

Vendor: BioLegend

Catalog Number: 344725

Alternative Catalog Numbers: 344726

Record Creation Time: 20250820T005645+0000

Record Last Update: 20250820T093710+0000

Ratings and Alerts

No rating or validation information has been found for Alexa Fluor(R) 647 anti-human CD8.

No alerts have been found for Alexa Fluor(R) 647 anti-human CD8.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 6 mentions in open access literature.

Listed below are recent publications. The full list is available at [nidm-terms](#) .

Zhang D, et al. (2025) Glutamine binds HSC70 to transduce signals inhibiting IFN- γ -mediated immunogenic cell death. *Developmental cell*, 60(14), 1958.

Laforêts F, et al. (2024) Protocol for real-time monitoring of CD8⁺ T and myeloid cell behavior in human high-grade serous ovarian cancer slices. *STAR protocols*, 5(2), 103102.

Laforêts F, et al. (2023) Semi-supervised analysis of myeloid and T cell behavior in ex vivo ovarian tumor slices reveals changes in cell motility after treatments. *iScience*, 26(4), 106514.

Kula T, et al. (2019) T-Scan: A Genome-wide Method for the Systematic Discovery of T Cell Epitopes. *Cell*, 178(4), 1016.

Lin JR, et al. (2018) Highly multiplexed immunofluorescence imaging of human tissues and tumors using t-CyCIF and conventional optical microscopes. *eLife*, 7.

Estes JM, et al. (2007) Efficacy of anti-death receptor 5 (DR5) antibody (TRA-8) against primary human ovarian carcinoma using a novel ex vivo tissue slice model. *Gynecologic oncology*, 105(2), 291.